Hemostemix Inc. (CVE:HEM – Get Free Report) shares traded down 14.5% during trading on Tuesday . The stock traded as low as C$0.27 and last traded at C$0.27. 438,482 shares traded hands during trading, a decline of 36% from the average session volume of 690,023 shares. The stock had previously closed at C$0.31.
Hemostemix Stock Performance
The business has a 50-day simple moving average of C$0.11 and a two-hundred day simple moving average of C$0.08. The company has a market capitalization of C$23.09 million, a price-to-earnings ratio of -13.25 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- 3 Dividend Stocks Rewarding Investors With Buybacks
- How Investors Can Find the Best Cheap Dividend Stocks
- Tech Titans in Chips: 3 Semiconductor Stocks Worth Buying Now
- How to Effectively Use the MarketBeat Ratings Screener
- Why SoundHound AI’s Setback Could Be a Buying Opportunity
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
